Eliseo Guallar
Eliseo Guallar
Scroll
Chair and Professor of the Department of Epidemiology
-
Professional overview
-
Dr. Guallar is an epidemiologist whose research is focused on the study of cardiovascular disease epidemiology and prevention, with an emphasis on evaluating the role of environmental and nutritional exposures in the development of cardiovascular disease. This research has made critically important and novel contributions to our understanding of risk factors for chronic disease both in the US and globally. He has published seminal articles and is a leading figure in an emerging field highlighting the risks of exposure to levels of metals previously considered safe for cardiovascular health. In addition to his work in toxic metals, Dr. Guallar has made important contributions to understanding the effects of certain micronutrients and vitamin supplements on cardiovascular disease risk and outcomes. Publications in this area were influential in changing consumer habits and attitudes towards these products. Much of this research has been funded by the National Institutes of Health, the Agency for Healthcare Research and Quality, the American Heart Association, the CDC, and other funders.
Dr. Guallar was the founding director of the Center for Clinical Epidemiology at the Samsung Medical Center and a lead investigator of the Kangbuk Samsung Cohort Study at the Kangbuk Samsung Hospital since its inception in 2010. Dr. Guallar has published over 500 research papers in peer-reviewed journals. He is also a Deputy Editor for Methods at the Annals of Internal Medicine and a past member and Chair of the Cancer, Heart, and Sleep Study Section at the National Institutes of Health.
Prior to teaching at NYU, Dr. Guallar was a Professor of Epidemiology and Medicine at the Johns Hopkins University Bloomberg School of Public Health and a core faculty member of the Welch Center for Prevention, Epidemiology, and Clinical Research at Johns Hopkins. In the Department of Epidemiology, Dr. Guallar was the Director of the Environmental and Occupational Area of Concentration and the Co-Director of the PhD Program. Dr. Guallar was also an adjunct Professor at the Department of Clinical Research Design and Evaluation of the Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, in Seoul, Korea.
-
Education
-
Diploma of English, Spanish Official School of Languages at Zaragoza (Escuela Oficial de Idiomas de Zaragoza), Zaragoza, SpainMD, University of Zaragoza, Zaragoza, SpainMPH, University of Minnesota, Minneapolis, MNDrPH, Harvard University, Boston, MA
-
Honors and awards
-
Six Honor Calls in the MD Program, University of Zaragoza School of Medicine (1981)Fellow of Spain’s Program of Training of Graduate Research of the Ministry of Education and Science, University of Zaragoza (1988)Fulbright Scholar, sponsored by Spain’s Ministry of Health and Consumer Affairs (1989)Faculty Innovation Award, Johns Hopkins University Bloomberg School of Public Health (2001)Scientist Development Award, American Heart Association (2002)Fellow of the American Heart Association, Council on Epidemiology and Prevention (2013)Advising, Mentoring, and Teaching Recognition Award 2014 – 2015, Johns Hopkins University Bloomberg School of Public Health (2015)High Impact Research Icon, University of Malaya (2015)
-
Publications
Publications
A Metabolomics Approach To Identify Metabolites Associated with Uremic Symptoms in Patients Receiving Maintenance Hemodialysis
AbstractAl Awadhi, S., Myint, L., Guallar, E., Clish, C. B., Wulczyn, K. E., Kalim, S., Thandhani, R., Segev, D. L., McAdams-DeMarco, M., Moe, S. M., Moorthi, R. N., Himmelfarb, J., Powe, N. R., Tonelli, M., Rhee, E. P., & Shafi, T. (n.d.).Publication year
2026Journal title
Kidney360Volume
7Issue
2Page(s)
353-361AbstractUremic symptoms are common in patients with kidney failure, but the chemicals causing them are unknown. We used state-of-the-art untargeted metabolomics and rigorous analyses to search for metabolites associated with uremic symptoms. We identified metabolite-symptom associations but could not replicate findings and offer recommendations for future research.Discontinuation of Beta-Blocker Therapy after Myocardial Infarction
Failed generating bibliography.AbstractPublication year
2026Journal title
The New England journal of medicineVolume
394Issue
13Page(s)
1302-1312AbstractThe role of long-term beta-blocker therapy after a myocardial infarction in patients without left ventricular systolic dysfunction or heart failure is unclear in the era of contemporary coronary-artery reperfusion and secondary prevention interventions.Mitochondrial heteroplasmy is a risk factor for the development of chronic lymphocytic leukemia
AbstractPasca, S., Hong, Y. S. S., Shi, W., Puiu, D., Lake, N. J., Lek, M., Guallar, E., Arking, D. E., & Gondek, L. P. (n.d.).Publication year
2026Journal title
Nature communicationsVolume
17Issue
1AbstractChronic lymphocytic leukemia (CLL) can arise from lymphoid clonal hematopoiesis of indeterminate potential (L-CHIP), but many individuals who develop CLL lack detectable L-CHIP prior to diagnosis. To identify additional predictors of CLL risk, we analyze mitochondrial heteroplasmy in 419,154 individuals from the UK Biobank (UKB). Heteroplasmy is associated with a 1.5-fold increased risk of developing CLL, and this risk rises to 4-fold when accounting for deleterious heteroplasmic variants. These findings are confirmed in an independent cohort, the All of Us Research Program (AoU). Notably, the associations remain significant even in the absence of L-CHIP, highlighting heteroplasmy's potential utility as an independent biomarker. Moreover, heteroplasmy is enriched in individuals with high-risk L-CHIP genotypes and large clonal burden, suggesting a potential biological role in malignant transformation. Here, we show that mitochondrial heteroplasmy, especially functionally deleterious variants, identifies individuals at increased risk of CLL who would otherwise go undetected by L-CHIP-based assessments.Clinical N Staging Subclassification for Stage III-N2 NSCLC Patients Undergoing Trimodality Therapy : A Good Beginning Is Half the Battle
AbstractLee, J., Hong, Y. S., Lee, J., Lee, G., Kang, D., Park, J., Jeon, Y. J., Park, S. Y., Cho, J. H., Choi, Y. S., Kim, J., Shim, Y. M., Guallar, E., Cho, J., & Kim, H. K. (n.d.).Publication year
2025Journal title
Annals of Thoracic SurgeryAbstractBackground: Lung cancer patients with stage III-N2 disease may benefit from the subclassification of nodal involvement before decision-making. We aimed to evaluate whether the clinical N descriptor subclassification predicts prognosis in patients undergoing trimodality therapy for stage III-N2 non-small cell lung cancer. Methods: Using our institutional registry between 2003 and 2019, we analyzed 899 consecutive patients with stage III-N2 non-small cell lung cancer undergoing neoadjuvant concurrent chemoradiotherapy followed by surgery. We subclassified clinical N2 into cN2a and cN2b on the basis of imaging and histopathologic results. Recurrence-free survival and overall survival were compared by N2 subclassification and separately by histologic type, using competing risks models and Cox proportional hazards models. Results: By the proposed N subclassification, 503 (56.0%) and 396 (44.0%) patients were assigned to cN2a and cN2b, respectively. During a median follow-up of 53.1 months, 492 patients had recurrence and 477 died. The hazard ratios for recurrence comparing cN2b with cN2a after adjustment for age, sex, comorbidities, clinical T category, and histologic type were 1.22 (95% CI, 1.03-1.46). The adjusted hazard ratios for mortality comparing cN2b to cN2a were 1.43 (1.19-1.71). When stratified by histologic type, cN2b had a higher risk of mortality compared with cN2a in both adenocarcinoma and squamous cell carcinoma. Conclusions: In our study evaluating the International Association for the Study of Lung Cancer's approach to subclassify the clinical N descriptor for stage III-N2 non-small cell lung cancer patients, cN2b had a higher risk of recurrence and mortality compared with cN2a, suggesting that clinical N subclassification may be a valuable predictor for stage III-N2 patients.Damage Control in the Wake of Political Action That Threatens the Integrity of Medical Research
AbstractLaine, C., Chang, S., Chopra, V., Cotton, D., Guallar, E., Wee, C., & Williams, S. (n.d.).Publication year
2025Journal title
Annals of internal medicineVolume
178Issue
5Page(s)
745-746Abstract~Deleterious mitochondrial heteroplasmies exhibit increased longitudinal change in variant allele fraction
AbstractKuiper, L. M., Shi, W., Verlouw, J. A., Hong, Y. S., Arp, P., Puiu, D., Broer, L., Xie, J., Newcomb, C., Rich, S. S., Taylor, K. D., Rotter, J. I., Bader, J. S., Guallar, E., van Meurs, J. B., & Arking, D. E. (n.d.).Publication year
2025Journal title
iScienceVolume
28Issue
6AbstractA common feature of human aging is the acquisition of somatic mutations, and mitochondria are particularly prone to mutation, leading to a state of mitochondrial DNA heteroplasmy. Cross-sectional studies have demonstrated that detection of heteroplasmy increases with participant age, a phenomenon that has been attributed to genetic drift. In this large-scale longitudinal study, we measured heteroplasmy in two prospective cohorts (combined n = 1404) at two time points (mean time between visits, 8.6 years), demonstrating that deleterious heteroplasmies were more likely to increase in variant allele fraction (VAF). We further demonstrated that increase in VAF was associated with increased risk of overall mortality. These results challenge the claim that somatic mtDNA mutations arise mainly due to genetic drift, instead suggesting a role for positive selection for a subset of predicted deleterious mutations at the cellular level, despite a negative impact of these mutations on overall mortality.Deleterious mitochondrial heteroplasmies exhibit increased longitudinal change in variant allele fraction
AbstractKuiper, L. M., Shi, W., Verlouw, J. A. M., Hong, Y. S. S., Arp, P., Puiu, D., Broer, L., Xie, J., Newcomb, C., Rich, S. S., Taylor, K. D., Rotter, J. I., Bader, J. S., Guallar, E., van Meurs, J. B. J., & Arking, D. E. (n.d.).Publication year
2025Journal title
iScienceVolume
28Issue
6Page(s)
112590AbstractA common feature of human aging is the acquisition of somatic mutations, and mitochondria are particularly prone to mutation, leading to a state of mitochondrial DNA heteroplasmy. Cross-sectional studies have demonstrated that detection of heteroplasmy increases with participant age, a phenomenon that has been attributed to genetic drift. In this large-scale longitudinal study, we measured heteroplasmy in two prospective cohorts (combined = 1404) at two time points (mean time between visits, 8.6 years), demonstrating that deleterious heteroplasmies were more likely to increase in variant allele fraction (VAF). We further demonstrated that increase in VAF was associated with increased risk of overall mortality. These results challenge the claim that somatic mtDNA mutations arise mainly due to genetic drift, instead suggesting a role for positive selection for a subset of predicted deleterious mutations at the cellular level, despite a negative impact of these mutations on overall mortality.Erratum : Long-Term Air Pollution Exposure and Mitochondrial DNA Copy Number: An Analysis of UK Biobank Data (Environ Health Perspect, (2023), 131, 5, 057703, 10.1289/EHP11946)
AbstractHong, Y. S., Battle, S. L., Puiu, D., Shi, W., Pankratz, N., Zhao, D., Arking, D. E., & Guallar, E. (n.d.).Publication year
2025Journal title
Environmental health perspectivesVolume
133Issue
5AbstractIn the second paragraph of the Introduction, the definition of particulate matters was incorrectly described as >10 lm in aerodynamic diameter for PM10 when it should have been ≤10 lm. Additionally, ≤2:5 lg should have been ≤2:5 lm. The corresponding sentence should have been described as follows: “We therefore evaluated the association between long-term exposure to air pollution [particulate matter ≤10 lm (PM10) and ≤2:5 lm in aerodynamic diameter (PM2:5), black carbon, and nitrogen dioxide (NO2)] with mtDNA-CN in over 45,000 adults from the UK Biobank study.” The authors regret the error.Framework to prioritize health outcomes of particulate matter exposure using national claims data
AbstractHeo, J., Lee, J., Woo, H., Nam, J., Kang, S., Kim, H., Lee, W., Ahn, K., Kang, D., Guallar, E., Kang, S. W. W., & Cho, J. (n.d.).Publication year
2025Journal title
PloS oneVolume
20Issue
12Page(s)
e0336511AbstractAlthough particulate matter (PM) exposure poses significant public health risks, previous research has focused on limited clinical areas. However, emerging evidence and pathological mechanisms of PM suggest that PM may exert broader systemic effects across a wide range of diseases. Therefore, we aim to identify and prioritize research questions to evaluate health impacts of PM exposure across various clinical specialties.Hazardous Environmental Pollutants and Cancer Disparities: A Systematic Review on the Consideration of Race and Ethnicity in Environmental Epidemiology Research
AbstractSchwalb, M. E., Visvanathan, K., Connor, A. E., George, C. M. M., Rule, A. M., Guallar, E., & Jones, M. R. (n.d.).Publication year
2025Journal title
Current environmental health reportsVolume
12Issue
1Page(s)
44AbstractThere are disparities in cancer incidence, mortality, and survival by race/ethnicity. As a result of structural mechanisms of discrimination, minoritized racial/ethnic groups are disproportionately exposed to higher levels of environmental carcinogens. Increased risk of exposure to harmful environmental pollutants may contribute to observed cancer disparities by race/ethnicity, but few studies have examined this effect. How race/ethnicity is operationalized in epidemiologic studies can impact interpretation of associations and potentially mask disparities, preventing the development of targeted public health interventions. We conducted a systematic review of epidemiologic studies on ambient environmental pollution and cancer outcomes in US adults and assessed how race/ethnicity was operationalized.Hearing changes and trajectories during the menopausal transition and their association with metabolic factors
AbstractJang, Y., Chang, Y., Lee, J., Seo, B., Cho, Y., Kim, M., Park, J. H. H., Kang, J., Kwon, R., Lim, G.-Y. Y., Kim, K.-H. H., Kim, H., Hong, Y. S. S., Park, J., Zhao, D., Cho, J., Guallar, E., & Ryu, S. (n.d.).Publication year
2025Journal title
MaturitasVolume
201Page(s)
108686AbstractHearing loss is an emerging public health concern, with women typically experiencing deterioration during menopause; however, longitudinal studies across this transition are limited. This study examined hearing changes across the menopausal transition in order to identify distinct patterns of hearing decline from 11 years before to 9 years after the final menstrual period, with the goal of informing strategies for early detection and intervention.Hearing changes and trajectories during the menopausal transition and their association with metabolic factors
AbstractJang, Y., Chang, Y., Lee, J., Seo, B., Cho, Y., Kim, M., Park, J. H., Kang, J., Kwon, R., Lim, G. y., Kim, K. H., Kim, H., Hong, Y. S., Park, J., Zhao, D., Cho, J., Guallar, E., & Ryu, S. (n.d.).Publication year
2025Journal title
MaturitasVolume
201AbstractBackground: Hearing loss is an emerging public health concern, with women typically experiencing deterioration during menopause; however, longitudinal studies across this transition are limited. This study examined hearing changes across the menopausal transition in order to identify distinct patterns of hearing decline from 11 years before to 9 years after the final menstrual period, with the goal of informing strategies for early detection and intervention. Materials and methods: We followed 4448 women aged 42–52 years who underwent regular health exams at the Kangbuk Samsung Hospital Total Healthcare Centers (2014–2018) through 2023. Hearing changes were analyzed using linear mixed-effects models across the menopausal transition. Group-based trajectory modeling was applied to assess heterogeneity in hearing deterioration relative to the final menstrual period. Results: A significant change in average bilateral hearing thresholds was observed across menopausal transition. Hearing change during the menopausal transition varied by obesity, with minimal change in those with obesity and slight improvement in those without during early transition. Group-based trajectory modeling identified two patterns: Group 1 (71.7 %) had stable hearing until the final menstrual period, then declined; Group 2 (28.3 %) showed poorer baseline hearing with a steeper, persistent decline. At baseline, Group 2 exhibited a significantly higher prevalence of overweight/obesity and hyperglycemia than Group 1. Conclusions: Postmenopausal stages were associated with significant hearing decline in middle-aged women. Furthermore, subgroups with metabolically unhealthy profiles exhibited poorer baseline hearing and a steeper decline in hearing, highlighting the need for appropriate screening and management during the menopausal transition.Impact of tumor size by clinical N subclassification and histology in trimodality-treated N2 non-small cell lung cancer
AbstractLee, J., Lee, J., Hong, Y. S. S., Lee, G., Park, J., Jeon, Y. J. J., Park, S.-Y. Y., Cho, J. H. H., Choi, Y. S. S., Kim, J., Shim, Y. M. M., Guallar, E., Cho, J., & Kim, H. K. K. (n.d.).Publication year
2025Journal title
Scientific reportsVolume
15Issue
1Page(s)
17195AbstractThe evolving TNM classification has emphasized the tumor size's role in NSCLC prognosis, reclassifying stage IIIA patients from the previous edition as stage IIIB (T3-4N2M0, 8th edition). However, the prognostic implications of tumor size and survival in stage III NSCLC patients undergoing neoadjuvant therapy remain unexplored. Therefore, we investigated the association between tumor size and mortality in N2 non-small cell lung cancer (NSCLC) patients undergoing neoadjuvant concurrent chemoradiotherapy followed by surgery (trimodality therapy), considering the number of metastatic N2 stations and histology. We analyzed 756 patients with stage III (T1-3N2) NSCLC who underwent trimodality therapy, excluding those with T3 tumors with invasion components or additional nodules (2003-2019). Overall survival was compared using the Cox-proportional hazards model, while the tumor size-survival relationship was estimated using restricted cubic splines. Using 8th TNM edition, 32.1%, 48.5%, and 19.3% were clinical T1, T2, and T3. During a median follow-up of 53.5 months, 398 patients died. The adjusted hazard ratios for overall survival comparing T2 and T3 to T1 were 1.46 (95% confidence interval, 1.14-1.85) and 1.48 (1.10-1.99). For the extent of clinical N2, large tumor size increased the mortality risk in patients with N2b but not in N2a. Tumor size did not increase mortality risk in squamous cell carcinoma patients; however, the mortality risk was increased with larger tumors in adenocarcinoma. These findings raise the importance of considering tumor size in treatment planning and suggesting tailored strategies.Impact of tumor size by clinical N subclassification and histology in trimodality-treated N2 non-small cell lung cancer
AbstractLee, J., Lee, J., Hong, Y. S., Lee, G., Park, J., Jeon, Y. J., Park, S. Y., Cho, J. H., Choi, Y. S., Kim, J., Shim, Y. M., Guallar, E., Cho, J., & Kim, H. K. (n.d.).Publication year
2025Journal title
Scientific reportsVolume
15Issue
1AbstractThe evolving TNM classification has emphasized the tumor size’s role in NSCLC prognosis, reclassifying stage IIIA patients from the previous edition as stage IIIB (T3-4N2M0, 8th edition). However, the prognostic implications of tumor size and survival in stage III NSCLC patients undergoing neoadjuvant therapy remain unexplored. Therefore, we investigated the association between tumor size and mortality in N2 non-small cell lung cancer (NSCLC) patients undergoing neoadjuvant concurrent chemoradiotherapy followed by surgery (trimodality therapy), considering the number of metastatic N2 stations and histology. We analyzed 756 patients with stage III (T1-3N2) NSCLC who underwent trimodality therapy, excluding those with T3 tumors with invasion components or additional nodules (2003–2019). Overall survival was compared using the Cox-proportional hazards model, while the tumor size-survival relationship was estimated using restricted cubic splines. Using 8th TNM edition, 32.1%, 48.5%, and 19.3% were clinical T1, T2, and T3. During a median follow-up of 53.5 months, 398 patients died. The adjusted hazard ratios for overall survival comparing T2 and T3 to T1 were 1.46 (95% confidence interval, 1.14–1.85) and 1.48 (1.10–1.99). For the extent of clinical N2, large tumor size increased the mortality risk in patients with N2b but not in N2a. Tumor size did not increase mortality risk in squamous cell carcinoma patients; however, the mortality risk was increased with larger tumors in adenocarcinoma. These findings raise the importance of considering tumor size in treatment planning and suggesting tailored strategies.Introducing Annals Guide to Journal Club : The Importance of Interpreting Clinical Research With Scientific Nuance
AbstractWee, C. C., Guallar, E., & Laine, C. (n.d.).Publication year
2025Journal title
Annals of internal medicineVolume
178Issue
3Page(s)
445-446Abstract~Longitudinal patterns and group heterogeneity of depressive symptoms during menopausal transition in middle-aged Korean women
AbstractJang, Y., Chang, Y., Park, J., Jeon, S. W. W., Seo, B., Park, J. H. H., Kang, J., Kwon, R., Lim, G.-Y. Y., Kim, K.-H. H., Kim, H., Hong, Y. S. S., Park, J., Zhao, D., Cho, J., Guallar, E., & Ryu, S. (n.d.).Publication year
2025Journal title
Epidemiology and psychiatric sciencesVolume
34Page(s)
e57AbstractWhile depressive symptoms are common during menopausal transition, the relationship between the two remains unclear. Therefore, this study aimed to examine the longitudinal changes in depressive symptoms among middle-aged Korean women and identify those with elevated and worsening symptoms during this period.Menopausal stage transitions and associations with overall and domain-specific perceived stress in middle-aged Korean women
AbstractJang, Y., Chang, Y., Jeon, S. W. W., Park, J., Seo, B., Kang, J., Kwon, R., Lim, G.-Y. Y., Kim, K.-H. H., Kim, H., Hong, Y. S. S., Park, J., Zhao, D., Cho, J., Guallar, E., & Ryu, S. (n.d.).Publication year
2025Journal title
MaturitasVolume
200Page(s)
108660AbstractThe menopausal transition, closely linked to later-life health, involves substantial physiological and psychological changes, potentially increasing perceived stress. However, longitudinal studies have reported inconsistent results, with limited data for Asian women, despite the potential for perceived stress to vary with both race and socioeconomic status. Therefore, this study investigated the longitudinal association between menopausal transition and perceived stress among middle-aged Korean women.Menopausal stage transitions and associations with overall and domain-specific perceived stress in middle-aged Korean women
AbstractJang, Y., Chang, Y., Jeon, S. W., Park, J., Seo, B., Kang, J., Kwon, R., Lim, G. y., Kim, K. H., Kim, H., Hong, Y. S., Park, J., Zhao, D., Cho, J., Guallar, E., & Ryu, S. (n.d.).Publication year
2025Journal title
MaturitasVolume
200AbstractBackground: The menopausal transition, closely linked to later-life health, involves substantial physiological and psychological changes, potentially increasing perceived stress. However, longitudinal studies have reported inconsistent results, with limited data for Asian women, despite the potential for perceived stress to vary with both race and socioeconomic status. Therefore, this study investigated the longitudinal association between menopausal transition and perceived stress among middle-aged Korean women. Materials and methods: We conducted a longitudinal study on 4619 women aged 42–52 who provided written consent in person at the Kangbuk Samsung Hospital Total Healthcare Center between 2014 and 2018. Participants were followed until August 2023, with a median follow-up of 6.6 years (interquartile range: 5.1–7.7), with 2 to 8 repeated comprehensive health screenings. We examined associations between menopausal transition and total scores and domain sub-scores (anger, tension, and depression) on the Perceived Stress Inventory using a linear mixed-effects model. Results: Overall Perceived Stress Inventory and anger scores significantly increased during the late transition stage compared with the pre-menopause stage; however, they decreased during post-menopause. Tension scores showed a similar trend, although the results were not significant. Depression scores significantly increased during the early transition, late transition, and post-menopause stages compared with the pre-menopause stage. Conclusion: Middle-aged Korean women's perceived stress significantly increased during the menopausal transition independent of age, marital status, education, and other confounders. Further research is needed to explore the implications of heightened stress and to assess the potential benefits of targeted interventions for women's health during this period.Menopausal stage transitions and their associations with overall and individual sleep quality in middle-aged Korean women
AbstractJang, Y., Chang, Y., Park, J., Kim, C., Jeon, S. W., Kang, J., Kwon, R., Lim, G. y., Kim, K. H., Kim, H., Hong, Y. S., Park, J., Zhao, D., Cho, J., Guallar, E., Park, H. Y., & Ryu, S. (n.d.).Publication year
2025Journal title
Journal of Affective DisordersVolume
368Page(s)
82-89AbstractBackground: Understanding the association between the menopausal transition and declining sleep quality can guide optimal timing for preventive interventions in transitioning women. However, studies lack representation of Asian women and sufficient data on the progression of menopausal stages and sleep quality changes over time in this population. Methods: This study included 3305 women in the pre-menopause stage at baseline. The sleep quality and its components were assessed using the Pittsburgh Sleep Quality Index (PSQI). Menopausal stages were classified as pre-menopause, early transition, late transition, and post-menopause according to the Stages of Reproductive Aging Workshop+10 (STRAW+10) criteria. We estimated the longitudinal association between menopausal stage changes over time and the PSQI score, and examined the effect of being overweight. Results: The trends in the PSQI scores and its components according to the menopausal stage changes over time showed that with the exception of sleep duration and habitual sleep efficiency, an overall decline was noted in sleep health during late transition and post-menopause compared to pre-menopause. These associations were independent of time-variant annual chronological aging, which was not significantly associated with sleep deterioration. Additionally, although the associations between menopausal stages and sleep quality did not significantly differ by adiposity level, the overweight group exhibited worse PSQI scores and components than did the non-overweight group. Limitation: Sleep quality and menopausal stage were assessed using self-reported questionnaires without objective measures. Conclusion: Our study underscores the importance of screening for sleep quality deterioration and implementing appropriate measures for women experiencing menopausal transition.Reporting guideline for Chatbot Health Advice studies: the CHART statement
Failed generating bibliography.AbstractPublication year
2025Journal title
BMC medicineVolume
23Issue
1Page(s)
447AbstractThe Chatbot Assessment Reporting Tool (CHART) is a reporting guideline developed to provide reporting recommendations for studies evaluating the performance of generative artificial intelligence (AI)-driven chatbots when summarizing clinical evidence and providing health advice, referred to as Chatbot Health Advice (CHA) studies.Reporting Guideline for Chatbot Health Advice Studies: The CHART Statement
Failed generating bibliography.AbstractPublication year
2025Journal title
JAMA network openVolume
8Issue
8Page(s)
e2530220AbstractThe rise in chatbot health advice (CHA) studies is accompanied by heterogeneity in reporting standards, impacting their interpretability.Reporting guideline for chatbot health advice studies: The CHART statement
Failed generating bibliography.AbstractPublication year
2025Journal title
Artificial intelligence in medicineVolume
168Page(s)
103222AbstractThe Chatbot Assessment Reporting Tool (CHART) is a reporting guideline developed to provide reporting recommendations for studies evaluating the performance of generative artificial intelligence (AI)-driven chatbots when summarizing clinical evidence and providing health advice, referred to as Chatbot Health Advice (CHA) studies. CHART was developed in several phases after performing a comprehensive systematic review to identify variation in the conduct, reporting and methodology in CHA studies. Findings from the review were used to develop a draft checklist that was revised through an international, multidisciplinary modified asynchronous Delphi consensus process of 531 stakeholders, three synchronous panel consensus meetings of 48 stakeholders, and subsequent pilot testing of the checklist. CHART includes 12 items and 39 subitems to promote transparent and comprehensive reporting of CHA studies. These include Title (subitem 1a), Abstract/Summary (subitem 1b), Background (subitems 2ab), Model Identifiers (subitem 3ab), Model Details (subitems 4abc), Prompt Engineering (subitems 5ab), Query Strategy (subitems 6abcd), Performance Evaluation (subitems 7ab), Sample Size (subitem 8), Data Analysis (subitem 9a), Results (subitems 10abc), Discussion (subitems 11abc), Disclosures (subitem 12a), Funding (subitem 12b), Ethics (subitem 12c), Protocol (subitem 12d), and Data Availability (subitem 12e). The CHART checklist and corresponding methodological diagram were designed to support key stakeholders including clinicians, researchers, editors, peer reviewers, and readers in reporting, understanding, and interpreting the findings of CHA studies.Response by Zhao et al to Letters Regarding Article, "intracranial Atherosclerotic Disease and Incident Dementia : The ARIC Study (Atherosclerosis Risk in Communities)"
AbstractZhao, D., Guallar, E., & Wasserman, B. A. (n.d.).Publication year
2025Journal title
CirculationVolume
151Issue
12Page(s)
e766Abstract~Safety and efficacy of antiplatelet therapy in patients with intermediate coronary artery stenosis and deferred revascularization
AbstractHong, D., Lee, S. H., Heo, J., Shin, D., Cho, J., Guallar, E., Joh, H. S., Kim, H. K., Ha, J., Choi, K. H., Park, T. K., Yang, J. H., Song, Y. B., Hahn, J. Y., Choi, S. H., Gwon, H. C., Kang, D., & Lee, J. M. (n.d.).Publication year
2025Journal title
Revista Espanola de CardiologiaAbstractIntroduction and objectives: This study investigated the safety and efficacy of antiplatelet therapy in patients with intermediate coronary artery stenosis who underwent deferred revascularization due to their fractional flow reserve (FFR). Methods: A nationwide cohort study was conducted using the Korean National Health Insurance Service database. A total of 4657 patients with intermediate coronary artery stenosis who underwent deferred revascularization due to their FFR were identified from 2013 to 2020. FFR was indicated in patients with no prior evidence of myocardial ischemia and intermediate coronary artery stenosis (50%-70%) as determined by quantitative coronary angiography. Patients were classified according to whether antiplatelet therapy was initiated after the index procedure. The primary efficacy outcome was major adverse cardiac and cerebrovascular events (MACCE), a composite of all-cause death, myocardial infarction, unplanned revascularization, and stroke, during a 5-year follow-up period. The primary safety outcome was any gastrointestinal bleeding. Results: After propensity score matching, there were 1634 patients in the antiplatelet therapy group and 1634 in the nonantiplatelet therapy group. The risk of MACCE was similar between the 2 groups (24.8% vs 24.7%; adjusted HR, 0.97; 95%CI, 0.84-1.13; P = 0.745). The risk of gastrointestinal bleeding was higher in the antiplatelet therapy group than in the nonantiplatelet therapy group (2.2% vs 1.2%; aHR, 2.07; 95%CI, 1.08-4.00). These results were similar in subgroup analyses. Conclusions: In patients with intermediate coronary artery stenosis who underwent deferred revascularization due to their FFR, antiplatelet therapy may increase the risk of gastrointestinal bleeding without reducing the risk of future ischemic events.Scalp cooling for preventing persistent chemotherapy-induced alopecia in anthracycline-treated patients : A single-arm trial
AbstractKang, D., Lee, H., Zhao, D., Kim, N., Kim, H., Kim, S., Kim, J. Y., Park, Y. H., Ahn, H. K., Guallar, E., Cho, J., & Ahn, J. S. (n.d.).Publication year
2025Journal title
Journal of the American Academy of DermatologyAbstract~